HHE Rheumatology 2019 | Page 24

EliA rheumatoid tests, best-in-class
for rheumatic disease diagnostic
1-20
Diagnostics that make a measurable difference to the
management of patients with rheumatic diseases
*EliA TM rheumatoid tests include EliA CTD Screen, EliA Symphony S , EliA CTD Single Parameters, EliA CCP, EliA RF IgM/IgA/IgG, EliA Cardiolipin IgG/IgM/IgA, EliA ß2-Glycoprotein I IgG/IgM/IgA, EliA
PR3 S , EliA MPO S 1. Thermo Fisher Scientific. Data on File. 2. Matthson Alm L, et al. Clin Exp Rheumatol 2017;36(1):144-152. 3. Alpini C, et al. (2010). “Role of a new FEIA assay in systemic connective
tissue disease diagnosis.” EliA Journal(Special Edition 1): 3. 4. Baptista-Fernandes I, et al. (2010). “Performance of a new screening test for connective tissue disease specific antibodies compared to
HEp2 screening.” EliA Journal(Special Edition 1): 4. 5. Bonroy C, et al. (2013). “Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope
interpretation.” Clinical Chemistry and Laboratory Medicine 51(9): 1771-1779. 6. Elhage, et al. (2013). “ANA SCREENING WITH THE ELIA CTD KIT IN PATIENTS WITH SYSTEMIC SCLEROSIS.”
Controversies in Rheumatology & Autoimmunity (CORA). 7. Jeong S, et al. PLoS ONE 2017;12(3). 8. Korsholm T, et al. Scandinavian Journal of Rheumatology 2014; 43: 89. 9. Martínez, MJ, et al. (2010).
“A comparison between two enzyme-linked immunosorbent assays and an indirect immunofluorescence test for Antinuclear Antibodies screening.” EliA Journal(Special Edition 1): 5. 10. Morozzi G, et al.
(2012). “A new strategy to detect ANA: IIF HEp-2 cells at second level after the EliA CTD Screen test. Is the algorithm correct?” ImmunoDiagnostics Journal 2: 3-4. 11. Op De Beeck K, et al. Autoimmunity
Reviews 2011;10(12): 801-808. 12. Otten HG, et al Clin Exp Rheumatol 2017;35:462-470. 13. Ougnou M, et al. Clinical Chemistry and Laboratory Medicine 2017;49:S215. 14. Pereira LM, et al. (2010).
“Evaluation of a novel automated CTD Screen for Connective Tissue Diseases.” EliA Journal (Special Edition 1): 6-7. 15. Robier C, et al. Clinical Chemistry and Laboratory Medicine 2016;54(8):1365-1370.
16. Sánchez-Castañón M, et al. (2010). “Evaluation of CTD Screen on the ImmunoCAP 100 System: Confirmed Diagnosis Samples and Consecutive Unknown Routine Samples.” EliA Journal (Special
Edition 1): 8-9. 17. van der Pol P, et al. Clin Chim Acta 2018;476:154-159. 18. Viander M, et al. (2011). “Clinical evaluation of EliA CTD Screen in CTD patients and control samples in comparison to ANA
immunofluorescence (IIF) on HEp-2 cells.” 10th Dresden Symposium on Autoantibodies, Dresden, September 2011. 19. Watanabe N, et al. The Japanese journal of clinical pathology 2014; 62(4):
315-323. 20. Willems P, et al. Clin Chem Lab Med 2018; 24: 909-918.
Find out more at allergyai.com/uk.lab
© 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of
Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COLXXXXX 0019